MVision uses artificial intelligence to automate cancer treatment planning with its unique automatic segmentation tool. Their next-generation technology speeds up the entire cancer treatment process, reducing treatment waiting times from weeks to days.
MVision AI, founded in 2017, is a pioneering, cloud-based software service provider for radiotherapy treatment planning. MVision uses artificial intelligence to automate cancer treatment with an AI-powered automatic segmentation tool that helps to standardize contouring and automate segmentation to streamline the radiotherapy treatment planning workflow. The company is announcing today its 5.4 million euros Post Seed funding round, led by J12 Ventures and Voima Ventures.
MVision is tapping into a global challenge. The aging population is increasing the prevalence of cancer. The International Agency for Research on Cancer estimates that the number of patients treated with radiotherapy will grow to 29 million by 2040.
“The burden of cancer is growing for patients, hospitals, and carers. Our cloud-based AI-powered technology provides faster and more reliable clinical decision-making for cancer patients undergoing radiotherapy treatment. With our automation, we can speed up the entire treatment planning process while still delivering high-quality care,” MVision’s Founder and CEO Mahmudul Hasan says.
MVision CEO Mahmudul Hasan wants to make same-day treatment a standard in cancer treatment globally.
With manual treatment planning, a patient diagnosed with cancer often needs to wait 2–3 weeks for treatment to start.
“Our automation enables same-day treatment. We are making same-day treatment a standard in cancer treatment globally,” Hasan adds.
More than 100 000 patients treated with MVision technology
MVision AI’s technology has been used to treat more than 100,000 cancer patients in 14 countries, with most patients originating in Finland, Sweden, Spain, France, the UK and the USA.
Significant treatment wait-time reductions have been achieved in many facilities, including the Gainesville Department of Radiation Oncology, University of Florida.
“We were immediately impressed by the quality and consistency of MVision’s AI auto-segmentation. It fits seamlessly and transparently into our workflow, saving many planners and physicians time. This AI-based auto-segmentation model covers the whole body – a hugely appreciated time saver for our busy clinical team”, tells Chihray Liu, PhD, DABR, FAAPM Professor and Chief of Physics-Gainesville Department of Radiation Oncology, University of Florida.
The scalable platform enables the improvement of cancer treatments worldwide
The recent 5.4 million euros round of funding will be used to develop new solutions to speed treatment and build a globally scalable cloud-based platform for cancer treatment. The funding round was led by Swedish J12 Ventures and Finnish Voima Ventures.
“MVision AI has arguably built the world’s best AI models to support oncologists with automated segmentation for radiotherapy to treat cancer. Hence, saving hospital costs and reducing waiting time for patients in need. We’re excited to back Mahmudul and his team as they scale the company, soon helping patients in need around the globe,” says Luca Banderet, Partner at J12 Ventures.
“We were impressed by the number of patients that have already been successfully treated with the help of MVision AI technology. Automating treatment processes enables faster care and more time to focus on patient care and human interactions that technology cannot replace,” says Pontus Stråhlman, Partner at Voima Ventures.